Edition:
United States

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

1.39USD
18 Jan 2019
Change (% chg)

$-0.13 (-8.55%)
Prev Close
$1.52
Open
$1.54
Day's High
$1.54
Day's Low
$1.38
Volume
28,087
Avg. Vol
17,705
52-wk High
$3.63
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

Novan says Nathan Stasko Stepped Down As President
Wednesday, 2 Jan 2019 06:15am EST 

Jan 2 (Reuters) - Novan Inc ::STASKO STEPPED DOWN AS PRESIDENT, AS CONTEMPLATED TO OCCUR AFTER KELLY MARTIN'S CEO APPOINTMENT.NOVAN ANNOUNCES MANAGEMENT CHANGES AND PROVIDES BUSINESS UPDATE.SAYS PRESIDENT DR NATHAN STASKO RESIGNED.PAULA BROWN STAFFORD PROMOTED TO PRESIDENT AND NEWLY CREATED ROLE OF CHIEF OPERATING OFFICER OF NOVAN.ENGAGED IN BUSINESS DEVELOPMENT DISCUSSIONS AROUND MID TO LATE-STAGE DERMATOLOGY ASSETS, WITH PARTICULAR FOCUS ON MOLLUSCUM.PAULA BROWN STAFFORD HAS BEEN PROMOTED TO PRESIDENT AND NEWLY CREATED ROLE OF COO.ADDED GASTROINTESTINAL (GI) DISEASES AS A THERAPEUTIC FOCUS AREA AS PART OF ITS OVERALL SCIENCE AND BUSINESS STRATEGY.INTENDS TO INITIALLY FOCUS ON PEDIATRIC GI DISEASES GIVEN FAVORABLE SAFETY PROFILE OF NITRIC OXIDE & EXISTING PRE-CLINICAL & CLINICAL DATA.BELIEVES THAT EXPANSION INTO GI WILL REQUIRE MINIMAL INVESTMENT.EXPANDING EXISTING NITRIC OXIDE PLATFORM BEYOND DERMATOLOGY WOULD INCREASE STRATEGIC AND FINANCIAL OPTIONS FOR CO.  Full Article

Novan To Present Data From SB414 Phase 1b Atopic Dermatitis Clinical Trial At 3rd Inflammatory Skin Disease Summit
Tuesday, 11 Dec 2018 08:00am EST 

Dec 11 (Reuters) - Novan Inc ::NOVAN TO PRESENT DATA FROM SB414 PHASE 1B ATOPIC DERMATITIS CLINICAL TRIAL AT 3RD INFLAMMATORY SKIN DISEASE SUMMIT.NOVAN INC - CLINICAL EFFICACY WAS NUMERICALLY GREATER FOR SB414 TREATED GROUPS COMPARED TO VEHICLE.NOVAN - STRONG ANTI-PRURITIC (ITCH) EFFECT SEEN IN STUDY AS MEASURED BY IMPROVEMENT ON PRURITUS (ITCH) NUMERIC RATING SCALE (NRS) COMPARED TO VEHICLE.NOVAN INC - INTENDS TO CONDUCT A PHASE 2 TRIAL FOR SB414.  Full Article

Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance In Preliminary Top Line Results
Wednesday, 14 Nov 2018 06:30am EST 

Nov 14 (Reuters) - Novan Inc ::NOVAN PHASE 2 MOLLUSCUM CONTAGIOSUM TRIAL ACHIEVES STATISTICAL SIGNIFICANCE IN PRELIMINARY TOP LINE RESULTS.NOVAN INC - END-OF-PHASE 2 MEETING TO BE REQUESTED IN 4Q 2018 AND PHASE 3 PROGRAM EXPECTED TO BEGIN IN 1H 2019.NOVAN INC - SAFETY AND TOLERABILITY PROFILES WERE FAVORABLE OVERALL WITH NO SERIOUS ADVERSE EVENTS REPORTED.NOVAN INC - IN PRIMARY ENDPOINT, 8% TWICE-DAILY WAS MOST EFFECTIVE DOSE WITH 41% COMPLETE CLEARANCE COMPARED TO 17% FOR VEHICLE.NOVAN INC - SECONDARY ENDPOINTS RECEIVED TO DATE ARE SUPPORTIVE OF AND CONSISTENT IN DIRECTION WITH PRIMARY ENDPOINT OF COMPLETE CLEARANCE.  Full Article

Novan Provides Update On SB414 Inflammatory Skin Disease Development Program
Tuesday, 15 May 2018 08:09am EDT 

May 15 (Reuters) - Novan Inc ::NOVAN PROVIDES UPDATE ON SB414 INFLAMMATORY SKIN DISEASE DEVELOPMENT PROGRAM.NOVAN INC - SB414 - NITRIC OXIDE-RELEASING CREAM - SAFE AND WELL-TOLERATED IN PSORIASIS PHASE 1B TRIAL.NOVAN - ATOPIC DERMATITIS-PHASE 1B CLINICAL TRIAL FULLY ENROLLED, CO CONTINUES TO TARGET RECEIPT OF INITIAL TOPLINE RESULTS IN Q3 2018.  Full Article

Novan Announces Pricing Of $38.0 Mln Offering Of Common Stock And Warrants
Friday, 5 Jan 2018 09:00am EST 

Jan 5 (Reuters) - Novan Inc ::NOVAN ANNOUNCES PRICING OF $38.0 MILLION OFFERING OF COMMON STOCK AND WARRANTS.NOVAN- PRICING OF OFFERING OF 10 MILLION SHARES OF COMMON STOCK, WARRANTS TO BUY UP TO 10 MILLION SHARES OF COMMON STOCK WITH AN EXERCISE PRICE OF $4.66.NOVAN INC - SHARES AND WARRANTS ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF $3.80 PER SHARE AND ACCOMPANYING WARRANT.  Full Article

Novan Announces Proposed Public Offering Of Common Stock And Warrants
Thursday, 4 Jan 2018 04:07pm EST 

Jan 4 (Reuters) - Novan Inc ::NOVAN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.  Full Article

Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414
Tuesday, 5 Dec 2017 08:35am EST 

Dec 5 (Reuters) - Novan Inc ::NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414.NOVAN INC - ‍ TOP LINE RESULTS FROM PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414​ ARE TARGETED FOR Q3 OF 2018.NOVAN INC - ‍TOP LINE RESULTS ARE TARGETED FOR Q2 OF 2018 FROM PREVIOUSLY ANNOUNCED PHASE 1B CLINICAL TRIAL WITH SB414 FOR TREATMENT OF PSORIASIS​.  Full Article

Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution
Tuesday, 7 Nov 2017 08:05am EST 

Nov 7 (Reuters) - Novan Inc ::Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​.Novan Inc - ‍proposed Phase 3 trial would be executed by third party's dermatology drug development team​.Novan Inc - a ‍new entity established by third party to provide capital to fund, expertise to execute additional Phase 3 pivotal trial for sb204​.  Full Article

Novan acquires IP rights to treat viral malignancies with nitric oxide
Wednesday, 18 Oct 2017 07:05am EDT 

Oct 18 (Reuters) - Novan Inc :Novan acquires IP rights to treat viral malignancies with nitric oxide.Novan Inc- ‍ Has initiated clinical development of company's nitric oxide platform in field of immunology​.Novan Inc- ‍Top line results for phase 1b trial of co's nitric oxide platform​ are expected in Q2 of 2018.Novan Inc- ‍Targeting to begin phase 1b trial with SB414 in adults with atopic dermatitis before year end with top line results expected in Q3 of 2018​.  Full Article

Novan Inc says files for mixed shelf of upto $150 million ‍​
Monday, 2 Oct 2017 04:32pm EDT 

Oct 2 (Reuters) - Novan Inc :Novan Inc says files for mixed shelf of upto $150 million - SEC filing‍​ ‍​.Novan Inc says in addition, may offer and sell up to 2.62 million shares common stock offered by selling stockholder.  Full Article